- Thursday, November 14th
- 12-2 p.m.
- Mindspace (100 E Penn Square, Philadelphia, PA 19107)
Neil Cooper is a co-founder and Executive Partner of Royer Cooper Cohen Braunfeld LLC (RCCB), a fast growing boutique law firm of more than 70 lawyers founded in 2012. RCCB attorneys think and act like entrepreneurs and business people, while serving a range of sophisticated clients in diverse industries, including a wide variety of both technology and traditional companies, both in the U.S. and Internationally.
Neil’s legal practice focuses on business transactions and corporate law matters, and he effectively serves as outside general counsel to many of his clients. He advises clients on structuring, negotiating, and documenting “bet-your-company” mergers and acquisitions, finance transactions, commercial transactions, and a broad range of business agreements, with emphasis on emerging growth and middle market companies, entrepreneurs, executives and investors in a variety of industries. Neil also counsels founders, executives, and investors with respect to equity positions, governance, employment arrangements, and agreements among investors.
Neil serves on the Boards of the Satell Institute and the Philadelphia-Israel Chamber of Commerce, where he was also a past President. He has been recognized by Chambers for Corporate/M&A & Private Equity (Pennsylvania: Philadelphia & Suburbs), named to the Philadelphia Titan 100 list in 2022 and 2023 and selected as a Pennsylvania Super Lawyer, Business and Corporate, from 2017 to the present.
Neil began his career as a member of the Business & Finance Section of the international law firm Morgan, Lewis & Bockius LLP. He received his J.D., 1995, from Columbia University School of Law, and his A.B., 1991, from Harvard College. He was also a Raoul Wallenberg Scholar at the Hebrew University of Jerusalem from 1991 – 1992.
Tiffany has spent over 20 years bringing innovative medical technology from bench to bedside and is known globally for her thought leadership on innovation and commercialization in life sciences and healthcare technology. In October 2020, she was appointed President and CEO of the Philadelphia-based Science Center to lead the organization’s next chapter focused on delivering economic, scientific, and civic impact. Operating at the intersection of startups, healthcare, and community, the Science Center drives inclusive economic growth across Greater Philadelphia and advances best-in-class healthcare solutions for all.
Tiffany joined the Science Center from the Global Center for Medical Innovation (GCMI) based in Atlanta where she was CEO. After a decade working in strategy, finance and business development in early-stage medical device companies, she was brought onboard to launch and operationalize GCMI in 2011. During her tenure, she catalyzed a capital efficient approach to move innovation to products that impact patient outcomes, bringing critical assets, infrastructure, and expertise needed to support entrepreneurs from concept through testing, regulatory submission and launch. Her work in building and strengthening the medical device ecosystem in Atlanta and the Southeast US was formally recognized by both Georgia Bio and Southeast Life Sciences.
Tiffany joined GCMI from Atlanta-based Scientific Intake where she served as Vice President of Business Development and Strategy, focusing primarily on the evaluation and piloting of global distribution channels and product development for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, a regenerative medicine and tissue engineering company that was acquired by Integra Lifesciences in 2020. At ACell, she led a broad range of initiatives, including corporate finance, investor relations, strategic and operational planning, business development, regulatory affairs, and reimbursement.
Tiffany began her career in management consulting and investment banking in the fintech industry where she developed a strong foundation in strategic, market, and financial analysis, M&A due diligence, and transaction structuring.
Tiffany serves on the Team Pennsylvania Board of Directors, the Chamber of Commerce for Greater Philadelphia Board of Directors, the Penn Health-Tech Strategic Advisory Board, the Drexel Applied Innovation External Advisory Board, and as an external advisor to the RADx program at the NIH. She served on the National Advisory Council on Innovation and Entrepreneurship (NACIE) of the U.S. Department of Commerce from 2014-2018. She was recognized by Philadelphia Business Journal in the Power 100 List in 2021 and 2022, Philadelphia Magazine’s “The 150 Most Influential Philadelphians 2023,” the Healthcare Technology Report’s Top 50 Healthcare Technology CEOs of 2021, Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Reviews “110 Women in Medtech to Know in 2017”.
Tiffany holds an MBA from the Georgetown University McDonough School of Business and a BBA in International Business from Loyola University New Orleans.
Audrey Greenberg is an award-winning executive with extensive experience in entrepreneurship, life sciences, technology, and investment. She has a remarkable track record of founding, scaling, and leading ventures that now hold multi-billion-dollar valuations. Over two decades, Audrey has served in leadership roles including Founder, CFO, CSO, CMO, and CBO, establishing herself as an expert in investing, real estate, pharma services, cell and gene therapy, and innovation ecosystems.
As the Founder and Chief Business Officer of CBM, Audrey was instrumental in driving business development, corporate strategy, investor relations, and joint ventures. Under her leadership, CBM earned multiple accolades and was acquired by SK pharmteco, part of the SK Group, Korea’s second-largest conglomerate.
Before launching CBM, Audrey built her career as a private equity executive, investment banker, and public accountant. She holds an MBA from the Wharton School and is a registered CPA in Illinois.
Audrey serves on the Board of Directors for NYMT, NLSP, ZSX, ARM, BFTP, the Chamber of Commerce, and KoP BID, and sits on Advisory Boards for Penn Medicine Abramson Cancer Center, Phacilitate, ISPE, PACT, and Philly Builds Bio. She actively participates in Women in Bio, the Forum of Executive Women, HBA, CEO Access Network, Women in Advanced Therapies, and Team Pennsylvania.
Her numerous honors include being named to the Medicine Maker Power List, Philly Power 100, and Titan 100 Hall of Fame, as well as receiving awards such as Leader of the Year and Power Woman.
Audrey is excited to join the Israel Tech Panel, contributing her insights on global innovation, entrepreneurship, and cross-border collaboration, alongside thought leaders from RCCB Law Firm and the University City Science Center.
